// App-Quantinova.ai

TCT75 : Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial

Researchers

Presenter

  • Freddy Abnousi

Principal Investigators

  • Vandana Sundaram

  • Jayne Prats

  • Manisha Desai

  • Robert Harrington

  • Deepak L. Bhatt

  • Kenneth Mahaffey

  • Efthymios N. Deliargyris

  • Gregg W. Stone

  • Christian Hamm

  • Philippe G. Steg

  • C. Michael Gibson

  • Harvey D. White

  • Matthew J. Price

  • Celina Yong

Medical Centers

  • Harvard Medical School, Boston, MA

  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

  • Stanford University Medical Center, Stanford, California, United States

  • Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand

  • Stanford University Department of Medicine, Stanford, CA

  • Kerckhoff Heart Center, Bad Nauheim, Germany

  • Scripps Clinic, La Jolla, United States

  • Stanford Univeresity Medical Center, Stanford, CA

  • Hopital Bichat, Paris, France, Paris, France

  • Stanford Univ, Palo Alto, CA

  • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

Locations

  • United States

  • Germany

  • France

  • New Zealand

Companies

  • The Medicines Compan

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Multi-vessel disease

  • Venous thrombosis

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • cangrelor

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved